Moderna and Pfizer vaccines prime T cells to fight variants – Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from…

Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.

Their new study, published online on July 1 in Cell Reports Medicine, shows that both CD4+ helper T cells and CD8+ killer T cells can still recognize mutated forms of the virus. This reactivity is key to the bodys complex immune response to the virus, which allows the body to kill infected cells and stop severe infections.

This study suggests that the impact of mutations found in the variants of concern is limited, says LJI Professor Alessandro Sette, Dr.Bio.Sci., study senior author and member of the LJI Center for Infectious Disease and Vaccine Research. We can presume that T cells would still be available as a line of defense against viral infection.

The researchers emphasize that the study only addresses how the bodys T cells respond to Variants of Concern (VOCs). The researchers emphasize that several of these variants, are linked to lower levels of virus-fighting antibodies.

The current study includes data on four of the most prevalent VOCs. Ongoing studies have been expanded to a larger panel of variants, including the Delta (B.1.617.2) variant, which became prevalent after this study had been initiated. The team has also established relationships with more than 20 different laboratories around the world to help monitor T cell reactivity to VOCs.

These variants are still a concern, but our study shows that even if there is a decrease in antibodies, as other studies have shown, the T cells remain largely unaffected, says LJI Instructor Alba Grifoni, Ph.D. The vaccines still work.

The Johnson & Johnson/Janssen COVID-19 vaccine was not part of this study because it was not available at the time the study was launched.

LJI findings guide COVID-19 vaccine efforts

This study was previously published online as a pre-print in March. The findings were then highlighted by National Institutes of Allergy and Infectious Diseases Director Anthony Fauci, M.D., in a March 31 White House press briefing.

Were learning more and more that these CD4+ and CD8+ T cells are very important in that they cross-react against certain viral variants, Fauci said.

In the time since the paper was first published, the researchers nearly tripled their patient cohort and performed an additional method of stringent statistical analysis. Weve also added an unexposed donor cohort, says study first author Alison Tarke, a Ph.D. student of the University of Genoa, guested in the Sette Lab at LJI.

For the new study, the researchers analyzed T cells from three different groups: people who had recovered from COVID-19, people who had received either the Moderna or Pfizer-BioNTech vaccines, and people never exposed to SARS-CoV-2 (from samples taken before the pandemic).

Both the recovered subjects and the vaccinated subjects were likely to have T cells that recognized the ancestral lineage of SARS-CoV-2. This was the original strain that emerged at the beginning of the pandemic; however, the virus has mutated since December 2019, and several variants have been identified as VOCs.

The question was whether people with T cells trained to recognize the ancestral strain would also recognize the new variants. The researchers tested T cell responses from the donor groups against four prominent VOCs: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Epsilon (B.1.427/B.1.429).

The researchers found that both vaccinated individuals and the recovered patients had cross-reactive T cells that could target these variants. That is good news for anyone who has received one of the two mRNA vaccines and for anyone who has recovered from any variant of the virus.

With this study, the underlying message is optimistic, adds Tarke. At least, as far as the T cell response goes, your immune system is still able to recognize these new variants and your T cells will be able to respond.

Similar results reporting largely unaffected T cell reactivity has now been presented through independent studies published in Nature and Science Immunology.

Study co-author and LJI Professor Shane Crotty, Ph.D., says this research highlights the importance of enlisting T cells in fighting SARS-CoV-2.

COVID vaccines do a fantastic job of making antibodies that stop SARS-CoV-2 infections, but some of the vaccines do less well at stopping infections from variants, Crotty says. You can think of T cells as a backup system: if the virus gets past the antibodiesif you have vaccine T cells the T cells can probably still stop the variant coronavirus infection before you get pneumonia.

Researchers are now looking for ways to take advantage of how flexible the T cells response appears to be. With T cells already working hard to recognize SARS-CoV-2 variants, Grifoni says future booster shots could increase immunity by prompting the body to produce more antibodies against the variants and/or by adding additional parts of the virus recognized by T cells.

T cell epitopes are well conserved among SARS-CoV-2 variants, so incorporating T cell targets into future COVID vaccines could be a clever way to make sure future variants cant escape the vaccines, adds Crotty.

There is also the possibility that current SARS-CoV-2 research may one day lead to a universal, pan-coronavirus vaccine. This kind of vaccine would train the body to recognize the structural details, such as elements of the spike protein, that all coronaviruses have in common.

This research shows that a pan-coronavirus vaccine is feasible, says Grifoni.

The group is now studying a much larger group of 12 different Variants of Concern (VOCs) and Variants of Interest (VOIs), including the Delta variant (B.1.617.2), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C37) and the variants B.1.526.1, B.1.617.3, R1 and B.1.1.519.

Sette says hed also like to study T cells from people who have been infected with the variants and see how those T cells react to the ancestral strain of the virus.

The study, Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals was supported by The National Institutes of Health's National Institute of Allergy and Infectious Diseases (AI142742, 75N9301900065, 75N93019C00001 and SARS-CoV-2 Assessment of Viral Evolution program (SAVE) ), the National Institutes of Health (grants U01 CA260541-01, AI036214), UC San Diego T32s (AI007036, AI007384), the Jonathan and Mary Tu Foundation, and a Clinical and Experimental Immunology Course at the University of Genoa, Italy.

Additional study authors include John Sidney, Nils Methot, Esther Dawen Yu, Yun Zhang, Jennifer M. Dan, Paul Rubiro, Aaron Sutherland, Eric Wang, Ricardo da Silva Antunes, April Frazier, Sydney I. Ramirez, Bjoern Peters, Richard Scheuermann, Stephen A. Rawlings, Davey M. Smith and Daniela Weiskopf.

See more here:
Moderna and Pfizer vaccines prime T cells to fight variants - Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from...

iShares Trust – iShares Genomics Immunology and Healthcare ETF (IDNA) falls -1.0280% for July 02 – Equities.com

Last Price$ Last TradeChange$ Change Percent %Open$ Prev Close$ High$ low$ 52 Week High$ 52 Week Low$ Market CapPE RatioVolumeExchange

IDNA - Market Data & News

iShares Trust - iShares Genomics Immunology and Healthcare ETF (NYSE: IDNA) shares fell -1.0280% to end trading Friday at $52.01 per share - a net change of $-0.54. Shares traded between $52.55 and $51.61 throughout the day.

Visit iShares Trust - iShares Genomics Immunology and Healthcare ETFs profile for more information.

The New York Stock Exchange is the worlds largest stock exchange by market value at over $26 trillion. It is also the leader for initial public offerings, with $82 billion raised in 2020, including six of the seven largest technology deals. 63% of SPAC proceeds in 2020 were raised on the NYSE, including the six largest transactions.

To get more information on iShares Trust - iShares Genomics Immunology and Healthcare ETF and to follow the companys latest updates, you can visit the companys profile page here: iShares Trust - iShares Genomics Immunology and Healthcare ETFs Profile. For more news on the financial markets be sure to visit Equities News. Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE:The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Read more:
iShares Trust - iShares Genomics Immunology and Healthcare ETF (IDNA) falls -1.0280% for July 02 - Equities.com

Immune system mutiny: mast cells and the mystery of long COVID – Salon

A year before the pandemic, I was diagnosed with a condition called mast cell activation syndrome (MCAS). A hallmark of the syndrome is hypersensitivities in more than one organ system: Food and other triggers can give me abdominal pain and severe diarrhea; my nose swells and I sneeze and wheeze. That sounds like allergies, but I've never tested positive on an allergy test.

Mast cells are among the immune system's first line of defense. They are abundant in the parts of the body that have close contact with the outside world, including the skin, airways, and intestines. Mast cells gone wrong cause allergic symptoms, secreting histamine and giving us itchy eyes, hives, and rashes. Less well understood is their role in modulating the responses of other immune cells. Before the pandemic, researchers had suggested that mast cell dysfunction could explain severe cases of the flu and highlighted the cells' role in shutting down inflammation in a variety of situations. In my case, probably because of a genetic peculiarity, my mast cells overreact.

I was fairly stable on my medication, and then I became sick with Covid-19. Months after the virus had passed and I no longer had pneumonia, I was still fighting fatigue and breathlessness. My symptoms also flared up erratically. On some mornings, for example, the oatmeal I had relied on for years could cause me abdominal pain. "Once the mast cell response is turned up, it doesn't wind down just because the infection is gone," explained my doctor, Leo Galland, a New York internist who specializes in difficult cases.

MCAS often seems to first emerge after a virus. Could it explain any of the symptoms of the growing group of patients with long Covid? Congress has now dedicated more than a billion dollars towards research into why so many post-Covid patients roughly a quarter, more often women still feel ill long after their infection. In Facebook groups and elsewhere, people with plausible symptoms for instance, severe lingering rashes and months of hives have been trading information about remedies for the disease. Severe fatigue after exercise suggested myalgic encephalomyelitis/chronic fatigue syndrome, which some say is linked to MCAS. Others became lightheaded when they stood up, which might mean they had postural orthostatic tachycardia syndrome (POTS). Spend an hour searching online, and you'll find papers saying POTS, too, may be a manifestation of MCAS.

But getting a workup for the syndrome can be a long ordeal. The full range of tests and treatments aren't routinely covered by insurance, leaving some patients to pay thousands of dollars out of pocket. Before you get there, you need to find a sympathetic doctor: Researchers don't agree on whether the illness is rare, or quite common.

I was lucky; Galland took me on in the 1980s. Long before the microbiome became a news item, he diagnosed me with intestinal dysbiosis a disturbed gut. We don't know why I got sick when I did, but when I showed up in Galland's office, I was a young woman on an absurdly limited diet with a myriad of fluctuating symptoms. On a trip to Tucson, as just one example, my face and arms ballooned, and then shrank on the plane home. I had been exposed to a fungus in the desert. My grandmother commiserated; when her face swelled up, her doctors in Antwerp, in the 1930s, pulled out all of her teeth. She had no explanation.

Interestingly, disturbances in the gut may be linked to severe Covid-19, and correcting them a possible path to health for long Covid sufferers. Mast cells may have a unique role in communicating with gut bacteria. In midlife, I fit the profile for irritable bowel syndrome (IBS), the abdominal pain, often accompanied by diarrhea or constipation, that afflicts as much as 20 percent of the population, and often sets in after a virus. Desperate, in 2018, I had just completed a trial of hypnotherapy for IBS when my digestion took an embarrassing turn, with accidents in taxis, and I could no longer eat outside my home.

A new dietician, Tamara Duker Freuman, author of "The Bloated Belly Whisperer," helped me identify the worst offenders: foods that are high in histamine, which can be found in everything from alcohol to avocados. After further testing, Galland put me on a regime: an arsenal of mast cell modulators and anti-histamines, including Pepcid, which also blocks histamine.

And I got better.

* * *

Mast cells were first named in 1878 by a German-Jewish Nobel Prize winner, Paul Ehrlich, a father of modern immunology who is most famous for discovering the cure for syphilis. At the turn of the century, scientists discovered anaphylaxis, the classic mast cell allergic reaction. The word comes from the Greek ana (against) and phylaxis (protection). The idea that an immune response could actually hurt us, rather than protect us, came as shock. Current research about the gut and immunity may change the paradigm again.

Five decades later, in 1949, scientists described a rare genetic disorder called mastocytosis, in which mast cells produce clones, building up in the skin, bones, and other organs. It wasn't until the 1980s that researchers began to notice that mast cells could become hyper-responsive or over-activated without cloning.

On a separate track, since the 1990s, researchers have explored mast cell activity in IBS. (A clinical trial of Pepcid and Zyrtec for difficult IBS cases is currently underway at the University of Cincinnati.) Kyle Staller, director of the Gastrointestinal Motility Laboratory at Massachusetts General Hospital, now sometimes prescribes Pepcid if he sees other signs like hives, to patients who ask him to consider a histamine or MCAS issue. "I think anyone who's been following the science closely has to start wondering, 'How much could this be playing a role in that IBS patient who's in front of us on a given day?'" he told me.

Competing proposals for diagnostic criteria emerged after 2010. Both proposals say that doctors should rule out other explanations for a person's symptoms, and that symptoms should appear in a least two organ systems (in my case, it affects my gut, nose, and skin). Both proposals require lab tests but they disagree on which tests are necessary, and on the ranges that would indicate someone has MCAS, as well as other details. Because lab results are elusive, Galland and some other doctors rely on a medical history instead.

The disagreement has led to two camps. In camp one, the condition is rare; in camp two, it occurs in up to 17 percent of the adult population. Specialists in camp one say patients are misled: "More and more patients are informed that they may have [mast cell activation syndrome] without completing a thorough medical evaluation," an international group of 24 authors, led by Peter Valent, a hematologist and stem cell researcher at the Medical University of Vienna, wrote in April 2019 in the Journal of Allergy and Clinical Immunology.

A year later, a largely American group of 43 authors led by Lawrence Afrin, one of the earliest mast cell activation researchers, countered in the journal Diagnosis that patients are suffering and even dying from underdiagnosis. By then the pandemic had arrived, and Afrin suggested that some patients with long Covid might be experiencing MCAS.

Patients were seeing links as well. For example, the distinct POTS symptom of extreme lightheadedness, once often dismissed as a problem of anxious young women, emerged as one of the odder long Covid symptoms. POTS, which has been reported by patients who experienced Lyme and other infections, may involve histamine and several other chemicals released by mast cells. It is known to overlap with MCAS.

Last fall, when the Centers for Disease Control and Prevention reported on what it labeled multisystem inflammatory syndrome (MIS), the name rang bells: MCAS is clearly a multi-system inflammatory syndrome. Theoharis Theoharides, a professor of immunology at Tufts University who has studied mast cells for more than 40 years, wrote that MIS patients should be evaluated for MCAS.

Mariana Castells, director of the Mastocytosis Center at Brigham and Women's Hospital in Boston, told me in an email that she's seen no data showing that long Covid patients have the requisite diagnostic markers of MCAS.

Observers agree that the long Covid group probably includes people with different vulnerabilities. It would be marvelous indeed, if, one day, we found a single powerful concept to understand post-viral illness.

In the meantime, you might not need to fit either group's criteria for MCAS, a difficult and chronic illness, to experience your mast cells' betraying you sometimes. "Like many, many conditions, over time we [may] learn that there's a spectrum of disease," Staller said. "It's not an all or nothing phenomenon."

Even the group that sees MCAS as rare acknowledges the existence of a less severe form of mast cell activation that does not meet MCAS criteria. Theoharides has detailed several categories of the illness. He told me that he'd guess half of patients diagnosed with IBS might have mast cell activation of some kind.

If mast cell dysfunction is truly common, I trust the online buzz to help us find out. Crowdsourcing on patient forums is here to stay. And it's good, after all, that sick people shared information, found support, and made long Covid a "thing" with ontological status.

Growing up, I had wondered if my grandmother's multiple "allergies" were real. We didn't laugh, but we didn't exactly believe her. Then it happened to me.

* * *

Temma Ehrenfeld is a writer and ghostwriter in New York drawn to philosophy and psychiatry. Her most recent book is "Morgan: The Wizard of Kew Gardens."

This article was originally published on Undark. Read the original article.

Original post:
Immune system mutiny: mast cells and the mystery of long COVID - Salon

AbbVie: Is the Price Right for Long-Term Investment? – The Motley Fool

As Foolish investors, we're seeking long-term success. That means paying attention not just to a company's operating fundamentals, but to how the market is valuing that company.

Imagine two investors, Anne and Barry. Both of them are interested in buying shares of a coffee company -- we'll call it Starfrancs. Both of them have researched Starfrancs's balance sheet and fundamentals, and they think it's a solid business. Starfrancs is fairly valued at $100, but Anne, who's paying less attention to valuation, buys her shares at $120. Meanwhile, Barry is able to buy them on a dip at just $80 each.

Image Source: Getty Images.

Even though both investors own the same company, Barry positioned himself with a much greater margin of safety in the event that the business doesn't perform as well as expected in the future. Buying the stock at a discount makes it more likely that Barry will benefit from capital appreciation in the stock price as Starfrancs reverts to its fair value.

So we can see it's important to consider fair value when determining whether a stock is worth buying. Let's take a look at pharma giant AbbVie (NYSE:ABBV), which is up 18% over the past year. Has this share price increase taken it past fair value?

In an effort to determine the fair value of AbbVie's shares, we will be using the discounted cash flow, or DCF, model.

The DCF model lets you estimate what a company is worth by estimating the sum of its future cash flows based on the previous year of cash flows. If the results are lower than the current share price, the company is likely not worth further consideration. However, results that are higher than the current share price imply a potentially enticing investment.

Here's the formula:

As fellow Fool Matthew Frankel writes in the linked article above, "That large symbol at the front of the formula is the Greek letter sigma, and it is used to denote the sum of several quantities. In other words, this symbol tells you to perform a present value calculation for each year's cash flow and then add them all together."

The first input into the DCF model is trailing-12-month (TTM) cash flow per share, though TTM earnings per share (EPS) can also be used. In AbbVie's case, these numbers are about the same. We'll opt to use AbbVie's TTM EPS, which is $11.09.

AbbVie's business is solid -- more on that below -- but as investors, we always want to leave ourselves with a margin of safety in case a company fails to meet our expectations. For that reason, we'll assume earnings growth will be 3% annually over the next five years -- well below the analyst consensus of 4.5%. What's more, while it is likely that AbbVie will deliver some level of earnings growth after that, we'll assume zero growth after five years.

Finally, we're using 10% -- the S&P's average annual return over the long term -- as our discount rate or required annual total return rate as a benchmark to adequately reward us for our efforts as investors.

We arrive at a fair value for shares of AbbVie of $125.55 a share, which is moderately higher than its current share price of $112.55. From this, we can conclude that AbbVie is undervalued.

Now that we know its fair value, let's talk about AbbVie's business. Its immunosuppressant Humira was the world's best-selling drug in 2019, and some investors have worried about what will happen when the drug goes off-patent in the U.S. in 2023. But the company has a number of paths, specifically within the oncology and immunology fields in which it is a leader, to stabilize its revenues and earnings.

Oncology and immunology are already the largest segments of the pharma industry by annual spending, and both are poised to benefit from 9% to 12% compound annual growth rates through 2025 (for other areas, that number is 5%). That should bring annual spending in each field to $273 billion and $175 billion, respectively, per FiercePharma.

AbbVie's oncology and immunology segments (which include Humira) comprised about 57% of the company's Q1 2021 revenue. That means the bulk of the company's sales are generated in the two most dominant, fastest-growing areas of pharma. And AbbVie is in a position to offset any near-term declines in Humira revenue with its two other immunology blockbusters, Skyrizi and Rinvoq, which combined saw year-over-year growth in excess of 100% to a combined $900 million in Q1 2021 -- further supporting the notion of massive demand in the immunology field of pharma. Further, AbbVie's two oncology drugs, Imbruvica and Venclexta, saw sales climb 7.3% year over year to a combined $1.7 billion in Q1 2021.

AbbVie is an industry leader in the rapidly growing oncology and immunology fields. It has a solid dividend of about 4.6% and is well positioned to guard against any loss of revenue from Humira. Its current price of about $113 looks like a moderate discount to fair value, making this company worthy of attention from investors looking to start or add to a position, anywhere below $125 a share.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Go here to read the rest:
AbbVie: Is the Price Right for Long-Term Investment? - The Motley Fool

Novartis says it overpaid Roche’s Genentech nearly $210M in a licensing dealand it wants its money back – FiercePharma

For years, Novartis said it dutifully shelled out tens of millions to Genentech as part of a patent licensing deal that dated back to 2005. Later, the Swiss pharma discovered it accidentally overpaid by nearly $210 million.

Those are the central arguments in a lawsuit filed by Novartis against its Swiss pharma counterpart seeking $209.5 million.In the suit, whichrecently made its way to California federal court, Novartis says Genentech isn't coughing up the dough.

Novartis claims Genentech was aware, or at least shouldve known, that the company was overpaying the entire time.

The paymentsstemmed from a 2005 licensing agreement Genentech struck with then Chiron Corporation related to its antibody patents. Novartis picked up Chiron a year later and developed several commercial antibody products from the pact, notablyimmunology meds Ilaris and Cosentyx, the suit says.

RELATED:Novartis hits setback in bid to block Regeneron's Eylea prefilled syringe as dual lawsuits drag on

Instead of alerting Novartis of the overpayments, Genentech continued to seek, accept, and retain the funds driven by Ilaris and Cosentyx sales, even though they werent entitled to them, Novartis argued in the filing.

While terms of the initial licensing deal weren't disclosed, Novartis maintains itperformed all or substantially all of its obligations under the deal and later learned of the overpayments after it expired.

Meanwhile, lawyers representing Genentech dismissed Novartis claims in a filing seeking to move the case from state to federal court, arguing the claims fall under federal patent law.

The companies werent immediately available for comment.

RELATED:Novartis' closely watched canakinumab hits a snag in lung cancer. What's next for the anti-inflammatory drug?

Cosentyx, which first launched in 2015, directly inhibits interleukin-17A (IL-17A), an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.

The treatment has become Novartis largest brand, driving $3.9 billion in sales last year, up 13% compared with the year prior.

Meanwhile, sales of IL-1beta inhibitor Ilaris came in at roughly $873 million, up 30%. Despite efforts to push the medicine, also known ascanakinumab,into fields outside immunology, Novartis has run intomultiple setbacks, including in heart disease, COVID-19 and, most recently, non-small cell lung cancer.

Read the original here:
Novartis says it overpaid Roche's Genentech nearly $210M in a licensing dealand it wants its money back - FiercePharma

Microbiome Medicine: Scientists Harness the Body’s ‘Bugs’ to Treat Asthma, MS, and More – UCSF News Services

Plenty of probiotic yogurts, pickles, and kombuchas claim to boost our digestive health with armies of microbes, but some scientists have more ambitious therapeutic plans for the bugs that colonize us. They hope to leverage these microbes as living therapeuticsfor a range of health conditions, including ulcerative colitis, multiple sclerosis, eczema, and asthma.

Remove this text and use the embed button to add an image.

UCSF launched a Living Therapeutics Initiative to accelerate the development and delivery of revolutionary treatments.

Learn More

Our guts, skin, and other regions of the body harbor trillions of microbes, as many as we have cells of our own. Each of these microbes bacteria, viruses, microscopic fungi, and others that make up the human microbiome brings with it a unique genome.

The composition of our microbiome and its microbial pan-genome is shaped by diet and environment, which in turn affect its important influences on human physiology, from digestion to brain health to immune function.

One real advantage of the microbiome is that its a dynamic system, said Susan Lynch, PhD, professor of gastroenterology and director of the UCSF Benioff Center for Microbiome Medicine. What were thinking about is how we can leverage microbes in engineering that system to improve health or prevent disease.

Much of the clinical research on the microbiome revolves around its connection with autoimmune disorders, such as rheumatoid arthritis, Crohns disease, and multiple sclerosis (MS), which altogether affect 24 million Americans. While genetics factor into why some people develop autoimmune disorders, environmental triggers likely contribute, said Sergio Baranzini, PhD, a neurology professor at the UCSF Weill Institute for Neurosciences, who studies the genetics and immunology of MS.

This is where we turn to the microbiome, he said. Because it is so influenced by food and other environmental factors, its a proxy for the environment.

A decade ago, when rapid DNA sequencing techniques made it cost-effective to identify bacteria, Baranzini began studying the relationship between the gut microbiome and MS, an autoimmune disorder in which the immune system attacks the nervous system. He had been intrigued by reports of other autoimmune conditions in which patients and controls were found to have different gut microbes.

In fact, most of our immune cells reside in our gut, and they depend on short-chain fatty acids produced when gut bacteria digest dietary fiber.

Baranzini compared stool and blood samples from people with MS to those from a member of the same household without MS. He found that the two populations of gut bacteria indeed differed, and that the blood from the person with MS had considerably fewer regulatory T cells, which normally tamp down the bodys immune response.

The deficiency of these T cells, Baranzini hypothesizes, is likely tied to the microbiome and impairs the bodys ability to control inflammation. He launched the International MS Microbiome Study to seek a comprehensive picture of gut microbiota in people with MS.

B cells (green), dendritic cells (blue) and T cells (red) are immune cells that help maintain the delicate relationship between the gut microbiome and the host. Image byLauren Rodda

Weve started discovering how diverse our microbiota are and how intimately they are in contact with our own immune systems, he said. And we now know that theres a lot of back-and-forth between the immune system and cells in the intestine that were only beginning to understand.

Microbial therapies for autoimmune disorders already exist in the form of fecal microbial transplants, or FMT, which involves taking stool samples from healthy individuals, isolating the gut microbes, and giving them to patients via a pill or enema.

This past April, Najwa El-Nachef, MD, an associate professor of medicine, wrapped up a clinical trial for ulcerative colitis and found that some patients respond much better to FMT than others, with a few reporting improvements in inflammatory skin and joint conditions as well. Her next step is to identify the best patients for microbiota-based therapy and to develop more targeted treatments.

For a subset of ulcerative colitis patients, manipulating the microbiome may provide a way to treat their autoimmune disease without suppressing their immune system, she said.

Our microbiome begins to take shape early, so interventions at the start of life can set the stage for future health. Lynch has focused some of her research on the gut microbiota during a babys first months of development. Its a critical time when the composition of the babys microbiome, influenced by the mother and the environment, can affect the development of the immune system and immune memory, with lasting consequences.

Susan Lynch, PhD, is the director of the UCSF Benioff Center for Microbiome Medicine. Photo by Barbara Ries

Najwa El-Nachef, MD, is studying the role of the microbiome in treatingulcerative colitis. Photo by Barbara Ries

Weve found that the gut microbiome at one month of age really predicts the risk of developing asthma and airway disease later in childhood, she said. Lynch and her team have identified specific microbial products that drive the dysfunction of regulatory T cells, which is associated with subsequent disease.

Weve considered that engineering the gut microbiome during this key window of immune training could have a long-term beneficial impact on the health status of high-risk children, she said

Lynch has developed a live microbial intervention administered at birth to babies at high-risk for asthma, comprised of bacteria that can modulate immune response. Their bacterial genomes encode a range of functions consistently absent from high-risk infant gut microbiomes.

The idea is to shape the developing gut microbiome by providing bacteria that can train the immune system early in life with their microbial products and metabolites, ultimately influencing the microbiomes function in the long term.

Our skin harbors its own set of microbes that interact with immune cells and protect the skin from infection.

Clinical trials using skin microbiota are already showing promise for patients with eczema, an autoimmune condition that can flare up when staph bacteria proliferate, said Tiffany Scharschmidt, MD, an associate professor of dermatology. The trials involve supplementing the bacteria that ordinarily keep the staph population under control.

Tiffany Scharschmidt, MD, is studying using skin microbiota arefor patients with eczema.Photo by Barbara Ries

Sergio Baranzini, PhD, is studying he genetics and immunology of multiple sclerosis.Photo bySteve Babuljak

As we gain more understanding of the interaction between the skin microbiome and its immune system, well see other microbial-based treatments emerging, she said. In the future, therapeutic skin microbes could even be genetically engineered to produce needed compounds.

The gut microbiome is, of course, intimately tied with digestion, producing diet-derived compounds that program immune cells and produce nutrients critical for the growth of the cells that line our intestines. The basic digestive and immune functions in our gut depend on colonization by specific bacteria, said Peter Turnbaugh, PhD, an associate professor of microbiology and immunology. Our intestinal cells have evolved receptors just lying in wait to sense the chemicals produced by the gut microbiome.

Turnbaugh has found that our inner critters also play a role in metabolizing medication. A better understanding of that role, he said, could increase drug efficacy.

We think the microbiome might be second only to the liver in determining how drugs are metabolized in the body, affecting how a patient responds to an existing therapy, he said.

Some antibiotics, for example, are activated by enzymes produced by the gut microbiota. Our microbial tenants may even influence how substances move around the body or change a drugs mechanism of action, but much remains unexplored in this area, said Turnbaugh.

Deeper knowledge of how our gut microbiome interacts with drugs might enable physicians to prescribe treatments that align with or supplement our individual microbiome, a new form of precision medicine.

Lynch believes that the therapeutic advances we can make through understanding the microbiome will rival those that came with understanding the human genome, particularly on autoimmune disorders.

Though the human microbiome field is still relatively young, it has already provided exceptional insights into the dependence of human physiology on our dynamic microbial inhabitants and offers a new set of tools to elicit better health, said Lynch. Translating these early observations into new live biotherapeutics represents the next step in realizing the potential of this field.

Read the rest here:
Microbiome Medicine: Scientists Harness the Body's 'Bugs' to Treat Asthma, MS, and More - UCSF News Services